Solventum (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating over the next 12 to 18 months, Wedbush Securities said in a Friday research note.

The brokerage said its investment thesis on Solventum centers on the divestiture or spin-off of its non-core Dental Solutions and Health Info Systems segments, adding that these businesses are "strategically misaligned" with the core Medical Surgical segment.

With activist investor Trian escalating its campaign for portfolio simplification, the company's "Transform for the Future" program targets EBIT margins between 23% and 25% by fiscal 2028 and includes the $4 billion Purification & Filtration divestiture. Wedbush said Solventum is seeing a convergence of catalysts that could unlock shareholder value.

The investment firm added that Solventum's stock offers an attractive entry point at current levels for investors seeking exposure to a differentiated medical technology portfolio with identifiable near-term catalysts, activist accountability, and a clear path to pure-play re-rating.

Wedbush initiated coverage with an outperform rating and a $94 price target.

Price: 75.43, Change: +1.01, Percent Change: +1.36